CYP Price Target post MSB FDA approval., page-7

The Nearology that our esteemed learned friend refers to, is of course called regulatory arbitrage by professionals, as you of course know, an aspect of broader statistical risk arbitrage trends in capital mkts. Outside of standard latency arbitrage, probably the biggest driver of algorithmic trading on programming of modern statistical inference models into trading models in capital markets in the last twenty years, following the advent of modern derivatives pricing models in the 1980's and 1990's.

That he calls it crap is rather like calling the entire notion of merger arbitrage (the next level up of course from regulatory arbitrage) a load of cods wallop.

Mkts certainly are a bit crap at pricing information efficiency at the smaller end (hence I like investing in them), but if he seriously thinks professional players are not already looking at alternatives to MSB is laughable. Its probably reflective of his bitterness that no-one pays enough attention to his myopic and errant essays on CYP and MSB.

To correct him, MSB does not say it is so. The markets actually said 'it is very much more likely' after the FDA's turnaround in March 2024 when they notified MSB that its clinical data was sufficient to refile a GVHD BLA. Yep absolutely zero correlative effect even ahead of the FDA's MSB decision - NOT:



I like your price call on yet another CRL for MSB, but will have to go with Hartleys on at least a $0.75 target on MSB gaining approval. We know ultimately CYP after all, has the better end product.

@JB1975 you'd best hope your refute of a massive risk arbitrage investment area of the bio-tech capital mkts as crap holds up if your 8,000 posts on MSB's impending failure actually come true. Perhaps you should familiarize yourself with risk arbitrage and hedge your concerns by selling some CYP. I am right there on the $0.22 bid waiting for you.